United Therapeutics (NASDAQ:UTHR) CFO Sells $209,609.40 in Stock

Posted by Defense World Staff on Apr 27th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 364 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40. Following the transaction, the chief financial officer owned 18,996 shares in the company, valued at $10,938,846.60. This represents a 1.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

James Edgemond also recently made the following trade(s):

On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The shares were sold at an average price of $572.21, for a total transaction of $5,513,815.56.
On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total transaction of $5,778,600.00.
On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00.
On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00.
On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total transaction of $5,778,900.00.
On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00.
On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $561.50, for a total transaction of $5,615,000.00.
On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00.
On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.
On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $567.16 on Monday. The firm’s 50 day moving average price is $536.51 and its 200-day moving average price is $494.61. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The stock has a market capitalization of $24.86 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 1.61 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter in the prior year, the business earned $6.19 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter worth $31,000. Wilmington Savings Fund Society FSB boosted its position in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in shares of United Therapeutics during the fourth quarter worth $48,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of recent analyst reports. Morgan Stanley raised their target price on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Wells Fargo & Company raised their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $601.50.

Check Out Our Latest Stock Analysis on UTHR

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.